Clinical Trials · NCT04515849
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 248
- Start date
- Aug 2020
- Locations
- 83 sites, 8 countries
- Primary endpoint
- The Primary Endpoint Was Percentage Change in UACR of Cotadutide at Different Dose Levels Compared to Placebo After 14 Weeks